BSW Wealth Partners Acquires Shares of 88,847 ChromaDex Co. (NASDAQ:CDXC)

BSW Wealth Partners bought a new stake in ChromaDex Co. (NASDAQ:CDXC) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 88,847 shares of the company’s stock, valued at approximately $324,000. BSW Wealth Partners owned approximately 0.12% of ChromaDex as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of CDXC. WINTON GROUP Ltd acquired a new stake in ChromaDex during the second quarter valued at approximately $597,000. Bank of New York Mellon Corp raised its position in shares of ChromaDex by 170.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after acquiring an additional 119,915 shares in the last quarter. Rhumbline Advisers bought a new position in ChromaDex during the second quarter worth $124,000. Perritt Capital Management Inc. bought a new position in shares of ChromaDex in the 1st quarter worth about $139,000. Finally, Renaissance Technologies LLC grew its position in shares of ChromaDex by 8.4% during the 2nd quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock valued at $1,136,000 after buying an additional 32,400 shares during the last quarter. Institutional investors and hedge funds own 15.41% of the company’s stock.

Insider Activity

In other ChromaDex news, Director Kristin Patrick sold 23,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $3.57, for a total value of $82,110.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 9.64% of the company’s stock.

ChromaDex Trading Up 67.9 %

Shares of NASDAQ CDXC opened at $5.86 on Monday. ChromaDex Co. has a 12-month low of $1.32 and a 12-month high of $5.98. The company has a market cap of $444.95 million, a PE ratio of 586.59 and a beta of 1.88. The stock has a 50 day simple moving average of $3.53 and a 200-day simple moving average of $3.23.

ChromaDex (NASDAQ:CDXC) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. The business had revenue of $25.58 million during the quarter, compared to the consensus estimate of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 5.06%. During the same quarter in the prior year, the company posted ($0.01) earnings per share. Sell-side analysts forecast that ChromaDex Co. will post 0.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of ChromaDex in a research note on Friday, August 9th.

ChromaDex Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.